Skip to content

Clinical observation of radiofrequency moxibustion in the treatment of abdominal obesity

Clinical observation of radiofrequency moxibustion in the treatment of abdominal obesity

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400086973
Enrollment
Unknown
Registered
2024-07-16
Start date
2024-06-13
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

obesity

Interventions

treatment group:radiofrequency moxibustion
control group:Governor moxibustion

Sponsors

Nanjing Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) meet the diagnostic standards of Chinese medicine and Western medicine; (2) Patients aged 20-70 years old, gender unlimited; (3) no weight-loss drugs or other weight-loss treatments have been taken in the past 3 months; (4) Voluntarily participate in the clinical trial, willing to cooperate with the treatment plan, and sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) The diagnosis was secondary obesity, such as thalamopathy, pituitary disease, hypothyroidism, hypercortisolism, hypogonadism, etc.; (2) Patients with severe injury of heart, brain, liver and kidney function, bleeding tendency, high fever, glaucoma, end-stage disease and other diseases; (3) Those with cognitive dysfunction or mental illness who cannot normally cooperate with examination and treatment; (4) Pregnant and lactating women, or people who are not sensitive to heat; (5) There are metal objects in the body. (6) Poor compliance, can not adhere to the treatment.

Design outcomes

Primary

MeasureTime frame
Abdominal girth;

Secondary

MeasureTime frame
Weight;Body mass index;Hip circumference;Visceral fat grade;Body fat percentage;Muscle content;Basal metabolic rate;Liver hardness measurement;Liver controlled attenuation parameters;Alanine aminotransferase;Aspartate aminotransferase;tetrapolipidemia;Fasting blood glucose;Fasting insulin;Fasting uric acid;Tumor necrosis factor;Interleukin-6;

Countries

CHINA

Contacts

Public ContactXie Xiaonan

Nanjing Hospital of Traditional Chinese Medicine

15951890725@163.com+86 159 5189 0725

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026